Obesity and type 2 diabetes: can we find a compromised treatment solution?
https://doi.org/10.14341/DM8726
Abstract
Type 2 diabetes and obesity are two enormous epidemic diseases of the 21st century. Because obesity is a primary risk factor for type 2 diabetes development, patients with diabetes are frequently obese. This comorbidity makes it challenging for these patients to not only compensate diabetes but also bring their weight back to normal. Several anti-diabetic drugs cause weight gain, which augments insulin resistance, and thus demands anti-diabetic treatment intensification. For the treatment, it is crucial to find an anti-diabetic treatment drug that is efficient but does not cause weight gain. In the last few decades, new anti-diabetic drugs with minimal or decrementing effects on the body weight have been introduced. New molecules appearing in the anti-obesity treatment are capable of not only reducing weight but also compensating diabetes. This study focuses on the current anti-obesity and anti-diabetic treatment and optimal combinations for treating comorbid patients.
Supporting agencies: Russian Science Foundation grant №17-15-01435
About the Authors
Gagik R. Galstyan
https://www.endocrincentr.ru/doctors/galstyan-gagik-radikovich
Russian Federation
Competing Interests:
Endocrinology Research Centre
Russian Federation
MD, PhD, Professor
Competing Interests:
lector, expert commitеee member of Astra Zeneka, Boeringer Ingelheim, Eli Lilly, MSD, Novartis, Novo Nordisk, Sanofi, Servier, Takeda
Ekaterina A. Shestakova
https://www.endocrincentr.ru/doctors/shestakova-ekaterina-alekseevna
Russian Federation
Competing Interests:
Endocrinology Research Centre; Lomonosov Moscow State University
Russian Federation
MD, PhD
Competing Interests:
lector, expert commitеee member of Astra Zeneka, Boeringer Ingelheim, Eli Lilly, MSD, Novartis, Novo Nordisk, Takeda
Igor A. Sklyanik
Endocrinology Research Centre; Lomonosov Moscow State University
Russian Federation
MD, PhD student
Competing Interests:
none
References
1. IDF Diabetes Atlas, issue 2015, available at: www.diabetesatlas.org.
2. Standards of Medical Care in Diabetes—2016. Obesity Management for the Treatment of Type 2 Diabetes. Diabetes Care. 2016;39(S1): S47-S51. doi: 10.2337/dc16-S009
3. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–1486. doi: 10.2337/dc10-2415
4. Mitri J, Hamdy O. Diabetes medications and body weight. Expert Opin Drug Saf. 2009;8(5):573–584. doi: 10.1517/14740330903081725
5. The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–154. doi: 10.1056/NEJMoa1212914
6. Lau DC, Teoh H. Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes. Can J Diabetes. 2015;39(5): S148–S154. doi: 10.1016/j.jcjd.2015.09.090
7. Pi-Sunyer F. Weight loss in type 2 diabetic patients. Diabetes Care. 2005;28(6):1526–1527. doi: 10.2337/diacare.28.6.1526
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 1998;352(9131):837–853. doi: 10.1016/S0140-6736(98)07019-6
9. Knowler WC, Barrett-Connor E, Fowler, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. doi: 10.1056/NEJMoa012512
10. Lindström J, Louheranta A, Mannelin M, et al. Finnish Diabetes Prevention Study Group. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003;26(12):3230–3236. doi: 10.2337/diacare.26.12.3230
11. The Diabetes Prevention Program (DPP) research group. The Diabetes Prevention Program (DPP). Description of lifestyle intervention. Diabetes Care. 2002;25(12):2165-2171. doi: 10.2337/diacare.25.12.2165
12. Moyer V. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. Annals of internal medicine. 2012;157(5):373–378. doi: 10.7326/0003-4819-157-5-201209040-00475
13. Carvajal R, Wadden TA, Tsai AG, et al. Managing obesity in primary care practice: a narrative review. Annals of the New York Academy of Sciences. 2013;1281(1):191–206. doi: 10.1111/nyas.12004
14. Wing RR, Lang W, Wadden TA et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–1486. doi: 10.2337/dc10-2415
15. Wadden TA, Volger S, Tsai AG, et al. Managing obesity in primary care practice: an overview with perspective from the POWER-UP study. International journal of obesity. 2013; 37(Suppl 1):S3–S11. doi: 10.1038/ijo.2013.90
16. Lim EL, Hollingsworth KG, Aribisala BS, et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011;54(10): 2506–2514. doi: 10.1007/s00125-011-2204-7
17. Steven S, Hollingsworth K, Al-Mrabeh A, et al. Very-Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiologic Changes in Responders and Nonresponders. Diabetes Care. 2016;39(5):808-815. doi: 10.2337/dc15-1942
18. The Look AHEAD Research Group. Eight-Year Weight Losses with an Intensive Lifestyle Intervention: The Look AHEAD Study. Obesity. 2014; 22(1): 5–13. doi: 10.1002/oby.20662
19. Rothberg AE, McEwen LN, Kraftson AT, et al. Very-low-energy diet for type 2 diabetes: an underutilized therapy? J Diabetes Complications. 2014;28(4):506–510. doi: 10.1016/j.jdiacomp.2014.03.014
20. Schwartz S, Herman M. Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies. Postgrad Med. 2015;127(5):480–493. doi: 10.1080/00325481.2015.1043182
21. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361(18):1736–1747. doi: 10.1056/NEJMoa0905479
22. Domecq JP, Prutsky G, Leppin A, et al. Drugs commonly associated with weight change: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(2):363–370. doi: 10.1210/jc.2014-3421
23. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443. doi: 10.1056/NEJMoa066224
24. Buse JB, DeFronzo RA, Rosenstock J, et al. The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes Care. 2016;39(2):198–205. doi: 10.2337/dc15-0488
25. Salpeter SR, Buckley NS, Kahn JA, et al. Meta-analysis: Metformin treatment in persons at risk for diabetes mellitus. Am J Med. 2008;121(12):149–157.e2. doi: 10.1016/j.amjmed.2007.09.016
26. Esquivel MA, Lansang MC. Optimizing diabetes treatment in the presence of obesity. Cleve Clin J Med. 2017;84(7 Suppl 1):S22-S29. doi: 10.3949/ccjm.84.s1.04
27. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care. 1999;22(6):960–964. doi: 10.2337/diacare.22.6.960
28. Foley JE, Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience. Vasc Health Risk Manag. 2010;9(6):541–548. doi: 10.2147/VHRM.S10952
29. Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12(9):780–789. doi: 10.1111/j.1463-1326.2010.01233.x
30. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin versus glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes, Obesity and Metabolism. 2009;11(2);157–166. doi: 10.1111/j.1463-1326.2008.00994.x
31. Шестакова М.В., Сухарева О.Ю., Чернова Т.О., и др. Комбинация ингибитора дипептидилпептидазы-4 и метформина в лечении больных сахарным диабетом 2-го типа: эффективный контроль гликемии, массы и количественного состава тела // Терапевтический архив. – 2013. – Т. 85. – №8. – С. 49-55. [Shestakova MV, Sukhareva OIu, Chernova TO, et al. A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition. Ter Arkh. 2013;85(8):49-55. (in Russ.)]
32. Ahrén B, Foley JE. Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. Diabetologia. 2016;59(5):907-917. doi: 10.1007/s00125-016-3899-2.
33. Matikainen N, Mänttäri S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia. 2006;49(9):2049–2057. doi: 10.1007/s00125-006-0340-2
34. Boschmann M, Engeli S, Dobberstein K, et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab. 2009;94(3):846–852. doi: 10.1210/jc.2008-1400
35. Vilsboll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomized controlled trials. BMJ. 2012;334(10):d7771. doi: 10.1136/bmj.d7771. doi: 10.1136/bmj.d7771
36. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, doubleblind, parallel-treatment trial. Lancet. 2009;373(9662):473–481. doi: 10.1016/S0140-6736(08)61246-5
37. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes. The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314(7):687-699. doi: 10.1001/jama.2015.9676
38. Valsamakis G, Konstantakou P, Mastorakos G. New targets for drug treatment of obesity. Annu Rev Pharmacol Toxicokl. 2017;57(1):585–605. doi: 10.1146/annurev-pharmtox-010716-104735
39. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. doi: 10.1056/NEJMoa1603827
40. Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2014;104(3):297–322. doi: 10.1016/j.diabres.2014.02.014
41. Yang X-P, Lai D, Zhong X-Y, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: Systematic review and meta-analysis. Eur J Clin Pharmacol. 2014;70(10):1149–1158. doi: 10.1007/s00228-014-1730-x
42. Scheen A. Pharmacodynamics, Efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33–59. doi: 10.1007/s40265-014-0337-y
43. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262–274. doi: 10.7326/0003-4819-159-4-201308200-00007
44. Garber A, Abrahamson M, Barzilay J, et al. Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2016 executive summary. Endocr Pract. 2016;22(1):84-113. doi: 10.4158/EP151126.CS
45. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Eng J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720
46. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-657. doi: 10.1056/NEJMoa1611925.
47. Дедов И.И., Шестакова М.В., Аметов А.С., и др. Инициация и интенсификация сахароснижающей терапии у больных сахарным диабетом 2 типа: обновление консенсуса совета экспертов Российской ассоциации эндокринологов (2015) // Сахарный диабет. – 2015. – Т. 18. – №1. – C. 5-23. [Dedov II, Shestakova MV, Ametov AS, Antsiferov MB, Galstyan GR, Mayorov AY, et al. Initiation and intensification of antihyperglycemic therapy in type 2 diabetes mellitus: Update of Russian Association of Endocrinologists expert consensus document (2015). Diabetes mellitus. 2015;18(1):5-23. (in Russ.)] doi: 10.14341/DM201515-23
48. Middleton KM, Patidar SM, Perri MG. The impact of extended care on the long-term maintenance of weight loss: a systematic review and meta-analysis. Obesity reviews. 2012;13(6):509–517. doi: 10.1111/j.1467-789X.2011.00972.x
49. Drucker DJ. Incretin-based therapy and the quest for sustained improvements in beta-cell health. Diabetes Care. 2011;34(9):2133–2135. doi: 10.2337/dc11-0986
50. Kahan S, Ferguson C, David S, Divine L. Obesity drug outcome measures: Results of a multistakeholder critical dialoque. Current Obesity Reports. 2013;2(2):128–133. doi: 10.1007/s13679-013-0052-0
51. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocrine practice. 2013; 19(2):327–336. doi: 10.4158/endp.19.2.a38267720403k242
52. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–362. doi: 10.1210/jc.2014-3415
53. Colman E, Golden J, Roberts M, et al. The FDA's assessment of two drugs for chronic weight management. The New England journal of medicine. 2012;367(17):1577–1579. doi: 10.1056/NEJMp1211277
54. Rissanen A, Lean M, Rossner S, et al. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. Int J Obes Relat Metab Disord. 2003;27(1):103–109. doi: 10.1038/sj.ijo.0802165
55. Finer N, Ryan DH, Renz CL, Hewkin AC. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Diabetes, obesity & metabolism. 2006;8(2):206–213. doi: 10.1111/j.1463-1326.2005.00481.x
56. Yanovski SZ, Yanovski JA. Long-term Drug Treatment for Obesity: A Systematic and Clinical Review. JAMA. 2014;311(1):74–86. doi: 10.1001/jama.2013.281361
57. Greenway FL, Caruso MK. Safety of obesity drugs. Expert Opin Drug Saf. 2005;4(6):1083–1095. doi: 10.1517/14740338.4.6.1083
58. Wadden TA, West DS, Neiberg RH, et al. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring). 2009;17(4):713–722 doi: 10.1038/oby.2008.637
59. Wadden T, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443-51. doi: 10.1038/ijo.2013.120.
Supplementary files
|
|
1. Рис. 1. Результаты исследования Look AHEAD (процент снижения массы тела через 1 и 8 лет наблюдения в группах интенсивного и стандартного подхода) [18]. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(38KB)
|
Indexing metadata ▾ | |
|
|
2. Рис. 2. Влияние сахароснижающих препаратов на массу тела [20]. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(25KB)
|
Indexing metadata ▾ | |
|
|
3. Рис. 3. Механизм влияния вилдаглиптина на метаболизм липидов. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(103KB)
|
Indexing metadata ▾ | |
Review
For citations:
Galstyan G.R., Shestakova E.A., Sklyanik I.A. Obesity and type 2 diabetes: can we find a compromised treatment solution? Diabetes mellitus. 2017;20(4):270-278. (In Russ.) https://doi.org/10.14341/DM8726
Views:
36593
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
